Akèy › Kansè tete negatif triple › Maryland
Etid klinik pou Kansè tete negatif triple nan Maryland
18 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT07619534A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Holy Cross Hospital ( Site 0069), Silver Spring
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
- MedStar Southern Maryland Hospital Center ( Site 0100), Clinton
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT03606967PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06245889A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
Ap rekrite
Laj 18 a 120 · Tout sèks · Mizajou Aug 21, 2026 · NCT07067138A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07327489Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- National Institute of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05660083Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT07311993A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- University of Maryland Medical Center (UMMC), Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 28, 2022 · NCT05627960Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.